Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million

Velan Capital Investment Management cut its Mineralys Therapeutics stake by 140,000 shares in Q1, with the trade valued at an estimated $4.11 million and the remaining position down to 11,000 shares worth $297,990. The holding now represents just 0.19% of AUM and has fallen outside the fund’s top five positions. The article is largely a factual SEC filing update, with broader context centered on Mineralys' pending FDA decision on lorundrostat due by Dec. 22, 2026.

Analysis

The important signal here is not the absolute size of the trim, but the timing: a meaningful de-risking ahead of a binary FDA event usually implies the manager is choosing to monetize option value rather than express conviction on approval probability. That matters because MLYS has already rerated hard; with a near-$2.5B market cap and no revenue, the stock is now trading as a regulatory success story, so any delay, label ambiguity, or safety language can de-rate the multiple quickly. In that setup, upside from approval is often less asymmetric than holders assume, while downside from an adverse CRL or conservative label can be abrupt and liquidity-driven.

The second-order read-through is stronger for competing aldosterone-pathway programs than for the broader biotech tape. If lorundrostat clears the FDA, it validates the commercial category and raises the bar for later entrants, but if the review becomes contentious it could pull forward skepticism on the whole resistant-hypertension pipeline, including management teams with similar mechanism claims. AstraZeneca is the more obvious comparative reference: weaker results from a rival candidate increase the relative importance of MLYS data, but they also mean the market may be over-assigning platform value to a single asset in a crowded cardio-metabolic opportunity set.

From a positioning standpoint, the stock now looks like a classic event-driven catalyst with positive carry only if you believe approval odds are still underpriced. The cleanest way to express that view is not outright long stock, but defined-risk upside exposure into the FDA date, because realized volatility should remain elevated and cash burn limits fundamental support. Conversely, the fund’s sale suggests the easier money may already have been made, and late-stage holders are vulnerable to a buy-the-rumor/sell-the-news outcome even if the decision is favorable.

Key Decisions for Investors

• Initiate a defined-risk bullish structure in MLYS: buy Dec-2026 call spreads or a call spread financed with a lower-strike put sale only if you are comfortable owning volatility into the FDA date; target a 2:1 reward/risk if approval comes with clean labeling.
• If already long MLYS, trim into strength over the next 1-2 weeks and keep a core position only through the FDA date; use a hard stop on any failure-to-approve headline or label concession that changes the commercial profile.
• Pair trade: long AZN vs short MLYS into the regulatory window if you think the market is overpaying for binary upside; AZN offers diversification and lower event risk, while MLYS is most exposed to disappointment.
• For event-driven books, buy short-dated MLYS downside protection rather than naked shorting; the stock can gap higher on approval, but downside from a negative decision is likely larger and faster than upside from a beat.
• Watch for post-FDA implied vol crush and consider selling rallies 24-72 hours after the decision if the stock gaps on approval but the label or commercial commentary is not meaningfully better than expected.